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from diagnosis is almost 90% at 30 days, 80% 
at one year, and only 60% at five years [4].
Coronary artery disease (CAD) is the 
primary cause in up to 60-70% of cases of 
systolic HF [5]. Valvular heart disease and 
IntroduCtIon
Heart failure (HF) is a chronic syndrome 
characterized by functional and structural 
cardiac abnormalities, which make the heart 
unable to maintain a flow rate adequate to 
the metabolic requirements of organs and 
tissues, if not at the cost of an increase of 
the filling pressures [1]. HF is a relevant 
problem to the healthcare worldwide and it 
is probably one of the most in-depth studied 
pathologies in clinical medicine. Its preva-
lence can reach 1-2% in the Western world 
(rising to 10% or more among persons over 
70 years of age) and its incidence can be es-
timated at 5-10 per 1000 persons per year 
[2]. Nevertheless, it is considered by physi-
cians a difficult condition to diagnose and 
manage [3].
HF has very high morbidity and mortal-
ity, particularly in the elderly. Survival rate 
Why we describe this case
Despite heart failure is a widespread 
and common disease, it is still problem-
atic to diagnose and manage. General 
practitioners should always focus on the 
clinical history and the physical exami-
nation, looking for suggestive signs and 
symptoms, not forgetting to listen care-
fully to the patients, who sometimes do 
not report the most important changes in 
their behavior or they just rapidly men-
tion them by chance 
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Case report
Abstract
Heart failure is one of the most common and intensely studied diseases in the world. Nevertheless, 
it is considered a difficult condition to diagnose and manage.
This case report, starting from the description of a brief clinical case, aims to directly and concisely 
explain the most important steps, from laboratory to bedside, in the diagnosis and management 
of heart failure disease. Physicians can rely on some laboratory tests (e.g., natriuretic peptides) 
and instrumental exams to diagnose and manage the patients in everyday medical practice. 
Finally, this article highlights that a multidisciplinary team management can improve the 
clinical status and the quality of life, thus preventing hospital admission and reducing mortality 
in patients with heart failure. 
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hypertension are two significant risk factors 
for HF, with a relative risk (RR) of 1.46 and 
1.40, respectively. Diabetes mellitus (DM) 
increases the risk of HF by directly causing 
cardiomyopathy and significantly contribut-
ing to CAD. Smoking, obesity, sedentary life, 
and a lower socioeconomic status are often 
neglected risk factors [6].
This article, starting from the description 
of a brief clinical case, aims to directly and 
concisely explain the most important steps, 
from laboratory to bedside, in the diagnosis 
and management of heart failure disease.
CAse report
A 74-year-old woman of Caucasian origin 
goes to her general practitioner (GP) for the 
onset of dyspnea with moderate efforts for 
a few days. In her medical history, she has 
been suffering from essential hypertension 
(treated with 5 mg/day of ramipril), chronic 
obstructive pulmonary disease (COPD) on 
stage B according to GOLD 2017 [7] (for 
which she was in therapy with salmeterol 
spray 50 µg twice a day) and a modest dys-
lipidemia (kept in check just by diet).
As soon as she entered the medical office, 
after a quick greeting, she exclaimed with 
concern: «You know doctor, I’m old, it’s true, 
but lately, while climbing the stairs, I feel 
breathless and in the evening my ankles are 
often swell». The GP, after having assessed 
that she was regularly taking all the previ-
ously prescribed medications, asked curi-
ously: «In the past few days, did anything 
new happen to you?». «No, doctor. My life 
is so ordinary and flat. Among other things, 
before I forget... I need you to prescribe me 
diclofenac! My right hip has started again to 
ache for a few weeks and my neighbor gave 
me this drug... and it’s really miraculous! 
Since I take it regularly every day, I feel no 
more pain in that area» she said.
The physical examination revealed that 
the blood pressure was 150/90 mmHg, the 
pulse was 105 beats per minute (bpm), the 
temperature was 36.8°C, the respiratory 
rate was 23 breaths per minute, the oxygen 
saturation was 96% while she was breath-
ing ambient air, her body mass index (BMI) 
was 25 (she reported a weight gain of 4 kg 
in the last few days), her skin was pale, and 
her peripheral pulses were normal. She had 
a distension of the jugular veins with ankle 
swelling. Her heart sounds were normal and 
rhythmic, with the presence of a third heart 
sound. At lung examination, bilateral basal 
crepitations were found, with mild wheez-
ing spread. Her abdomen was soft and non-
tender, with palpable hepatomegaly (2 cm 
below costal margin), and abdominojugular 
reflux sign was positive.
dIsCussIon
1. What is the most likely diagnosis? 
(signs and symptoms)
Taken together, these clinical features are 
suggestive for congestive heart failure condi-
tion, precipitated by the intake of non-steroidal 
anti-inflammatory drugs (NSAIDs).
The cardinal signs (i.e., pulmonary crepi-
tations and/or peripheral edema) and symp-
toms (i.e., dyspnea) of heart failure are not 
specific and must be evaluated in light of the 
patient’s history, the physical examination, 
and the findings of additional tests [8,9]. 
Other signs (e.g., enlarged heart, jugular 
vein distention, and a third heart sound) 
and symptoms (e.g., paroxysmal nocturnal 
dyspnea and orthopnea) have a diagnos-
tic specificity ranging from 70% to 90%, 
but a low sensitivity, ranging from 11% to 
55% [10].
The presence of COPD in the patient’s 
clinical history may be an important con-
founding factor in the differential diagnosis. 
However, the onset of peripheral edema, the 
rapid worsening of dyspnea, the pharmaco-
logical anamnesis, and the absence of fever 
and sputum make the hypotheses of wors-
ening of the obstructive disease or bronchi-
tis exacerbation less likely. One of the GP’s 
tasks is to keep hypertensive patients under 
control avoiding organ complications, but 
this is sometimes hampered by the poor 
What should the clinician ask him/
herself or the patient?
1. What is the most likely diagnosis?
2. What strategy should be adopted to make 
a certain diagnosis?
3. How should this condition be managed?
4. Does this condition require hospital-
ization?
5. How should this condition be fol-
lowed up?
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has a 90% negative predictive value for ex-
cluding systolic heart failure [16].
Chest radiography is useful to detect fea-
tures suggestive for heart failure (such as 
pleural effusions and pulmonary edema) and 
to rule out other causes of breathlessness, like 
malignancies or infections [17].
Transthoracic echocardiography (TTE) 
allows the confirmation of the diagnosis, 
provides information on valvular and myo-
cardial structure, and may detect other im-
portant features, such as myocardial diastolic 
and/or systolic function of right and/or left 
ventricles. TTE is also fundamental to dis-
tinguish heart failure with preserved ejection 
fraction (HFpEF) from heart failure with 
reduced ejection fraction (HFrEF), which 
differ in both prognosis and treatment [18].
It is also important to prescribe blood 
tests, such as [19]:
 y full blood count: to rule out anemia that 
may precipitate HF or offer an alterna-
tive explanation for breathlessness and to 
exclude neutrophilia that may suggest an 
infective cause of breathlessness;
compliance of some patients in taking ther-
apy and undergoing examinations.
Taking into account these considerations, 
a targeted medical history is of the utmost 
importance, keeping in mind that what can 
be useful for a physician may not always 
coincide with what the patient believes it is 
important to tell.
Hence, it’s essential to remember some 
questions to ask about, such as [11]:
 y How far can she walk before being out 
of breath?
 y How many pillows does she use for sleep-
ing?
 y Does she wake up at night due to the feel-
ing of breathlessness?
 y Had she recently got chest pain?
 y Did she recently take on her own initia-
tive any drug that might exacerbate heart 
failure (such as steroids or NSAIDs)?
2. What strategy should be adopted to 
make a certain diagnosis? 
(essential initial investigations)
The GP prescribed natriuretic peptides, elec-
trocardiogram, chest radiography, transthoracic 
echocardiography, and some blood tests.
Natriuretic peptides (NPs) are a group of 
neurohormones that play an important role 
in fluid homeostasis [12]. Their plasma con-
centration is useful as early diagnostic test, 
particularly in non-acute setting, when 
echocardiography is not immediately acces-
sible (Figure 1). Patients with normal NP 
concentration are unlikely to have HF [13], 
and they can avoid echocardiography. In fact, 
the B-type natriuretic peptide cut-off level 
of 35 pg/ml has a negative predictive value 
of 93% [14]. However, in this case the doc-
tor decided to request a transthoracic echo-
cardiography immediately, due to the strong 
suspicion of HF and in order to shorten the 
waiting times for the execution of this exam.
Even if the use of serial measurements 
of natriuretic peptides can be helpful in 
some specific cases in guiding therapeutic 
decisions, indicating the need to intensify 
the pharmacological treatment [15], this 
approach should not be recommended [8].
Electrocardiogram (ECG) is inexpensive, 
can be obtained immediately, and provides 
useful information about heart rhythm and 
electrical conduction. It may also show evi-
dence of left ventricular hypertrophy or pre-
vious infarct. A normal electrocardiogram 
Figure 1. Diagnostic 
algorithm for heart 
failure. Modified 
from [8]
BNP=B-type natriuretic 
peptide; 
CAD=coronary artery 
disease; 
ECG=electrocardiogram 
HF=heart failure; 
MI=myocardial infarction; 
NT-proBNP=N-terminal 
pro-B type natriuretic 
peptide
a Patient reporting 
symptoms typical of HF
b Normal ventricular and 
atrial volumes and function
c Consider other causes of 
elevated natriuretic peptides
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 y thyroid status: hypothyroidism and hy-
perthyroidism are important risk factors 
to develop HF and they need an appro-
priate treatment;
 y liver function tests: to reveal hepatic con-
gestion resulting from a right HF and 
because hypoalbuminemia may result in 
fluid retention and consequent periph-
eral edema;
 y renal function tests: renal failure may re-
sult in fluid overload, and a baseline renal 
function is crucial for treating HF with 
diuretics and angiotensin-converting en-
zyme (ACE) inhibitors, that may worsen 
renal function and cause electrolyte dis-
equilibrium;
 y lipid profile and glycated hemoglobin: to 
evaluate cardiovascular risk.
3. How should this condition 
be managed? 
(the medical therapy)
While waiting for the results of the required 
clinical tests, the GP prescribed the immediate 
discontinuation of NSAIDs, the beginning of 
diuretic therapy with the addition of furosemide 
(50 mg/day by mouth), and the revaluation of 
antihypertensive therapy with a dose escalation 
of ramipril to 7.5 mg/day.
First of all, on the basis of the Hippocratic 
principle primum non nocere, it is essential to 
avoid all drug treatments that might exacer-
bate HF (e.g. NSAIDs, the probable cause of 
heart failure precipitation in this case). It is 
demonstrated that high doses of commonly 
used NSAIDs could double the risk of de-
veloping a new heart failure [20] or easily 
induce an exacerbation of a pre-existing one 
with an increase in hospitalizations [21]. 
Diuretics are useful to decrease the signs 
and symptoms of congestion in patients with 
HF [22], even if their effects on morbidity 
and mortality have not been analyzed in 
randomized controlled trials [8]. The aim 
of diuretic therapy is to reach and maintain 
euvolemia with the lowest achievable dose. 
The dose of the diuretic must be modified 
according to the individual necessities over 
time [11].
The beneficial effects of ACE inhibitors in 
heart failure include improvements in sur-
vival chance, rate of hospitalization, symp-
toms, cardiac performance, neurohormonal 
levels, and reverse remodeling [23]. It’s criti-
cal to increase (like the GP did in this case) 
ACE inhibitor (for example, doubling the 
dose every 2-4 weeks) until the target dose is 
achieved or side effects appear. Renal func-
tion tests should be performed within 1-2 
weeks from each dose increment to check 
that blood creatinine levels and estimated 
glomerular filtration rate are stable and hy-
perkalemia is absent [11].
Angiotensin receptor blockers (ARBs) are 
recommended only as an alternative in pa-
tients intolerant to ACE inhibitors because 
of severe cough or angioedema [24].
Beta-blockers (BBs) have a protective ef-
fect on the heart, exerted through the inhibi-
tion of adrenergic system with inotropic and 
negative chronotropic effects. The use of BBs 
results in a reduction in mortality, morbidity, 
and hospitalization for HF exacerbation and 
improves the severity of symptoms [25]. The 
treatment with BBs should be initiated in 
stable patients and gradually up-titrated to 
the maximum tolerated dose, while, in case 
of exacerbation of chronic HF, it must be re-
duced or discontinued or not started (like in 
this case) [26]. Furthermore, the administra-
tion of BBs, especially cardioselective ones, in 
patients with COPD is safe and the presence 
of a COPD is no longer a contraindication 
to the use of BBs in a patient with HF [27].
Recently, a new therapeutic class of drugs 
called angiotensin receptor neprilysin in-
hibitors (ARNI) has been developed. They 
act on the renin-angiotensin-aldosterone 
system (RAAS) and the neutral endopep-
tidase system. Sacubitril/valsartan, the first 
medication of this new class, is recommend-
ed as a replacement for an ACE inhibitors 
to further reduce the risk of death and HF 
hospitalization in patients with HFrEF 
who remain symptomatic despite optimal 
treatment with BBs, ACE inhibitors, and 
mineralocorticoid receptor antagonists [28].
All the foregoing considerations are valid 
only for patients with HFrEF. Conversely, 
no therapy significantly improves survival 
or prevents hospitalizations in patients af-
fected by heart failure with normal ejection 
fraction. The objective in these patients is to 
relieve symptoms with diuretics and treat 
hypertension and other comorbidities [29].
Outcomes
The ECG revealed a sinus rhythm and a 
left bundle branch block (LBBB) in ad-
dition to the findings reported in Table I.
A severe cardiomegaly was apparent at 
the chest radiography, which revealed 
also bibasilar pulmonary edema with 
bilateral small pleural effusions.
Blood tests highlighted 4 parameters out-
side the normal range (Table II).
Transthoracic echocardiogram (TTE) 
was not yet run.
parameter detected value
Heart rate 62 bpm
PQ 0.20 s
QRS axis -30°
QRS 0.18 s
table I. 
Electrocardiography 
findings
parameter detected value normal range
Hemoglobin (g/dl) 8.1 11.5-15.5
Mean Corpuscular Volume (fl) 78 80-97
Creatinine (mg/dl) 2.4 0.6-1.5
Brain Natriuretic Peptide (pg/ml) 280 < 35
table II. Blood test 
results
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4. does this condition require 
hospitalization? 
(the hospitalization)
On the basis of the above-mentioned data, 
that confirmed the initial suspicion of NSAIDs-
induced heart failure and showed an acute renal 
failure and an acute anemia (both not previ-
ously present), the GP decided to hospitalize 
the patient.
HF is the most common reason of hos-
pitalization in patients over 65 years of age 
[30]. Unfortunately, evidence from the lit-
erature to guide the decision about the hos-
pitalization of a HF patient is scarce [31]. 
Therefore, patient’s hospitalization depends 
on numerous subjective factors, including 
both the severity of underlying condition 
and comorbidities. In this case, the deci-
sion was related to the need to understand 
the underlying etiology of a first episode of 
HF in a complex patient with multicomor-
bidity (COPD, acute renal failure, and ane-
mia). Moreover, the concomitant presence 
of severe cardiomegaly and LBBB (already 
present in previous ECGs, but the patient 
had never wanted to undergo more exami-
nations) made the GP suspect the presence 
of a HFrEF, that must be confirmed by the 
execution of a TTE, and eventually treated 
with a cardiac resynchronization therapy 
implantation [32].
Furthermore, the hospitalization is neces-
sary to perform intravenous diuretic therapy 
with a strict monitoring of hydro-balance 
and kidney function, in light of the finding 
of concomitant acute renal failure. It is also 
important to understand the etiology of ane-
mia and treat it (the hypothesis of a gastro-
intestinal bleeding connected to the use of 
NSAIDs is plausible): anemia is another in-
dicator of the grade of severity of this clinical 
The dose of the diuretic must be modified 
according to the individual necessities over 
time [11].
The beneficial effects of ACE inhibitors in 
heart failure include improvements in sur-
vival chance, rate of hospitalization, symp-
toms, cardiac performance, neurohormonal 
levels, and reverse remodeling [23]. It’s criti-
cal to increase (like the GP did in this case) 
ACE inhibitor (for example, doubling the 
dose every 2-4 weeks) until the target dose is 
achieved or side effects appear. Renal func-
tion tests should be performed within 1-2 
weeks from each dose increment to check 
that blood creatinine levels and estimated 
glomerular filtration rate are stable and hy-
perkalemia is absent [11].
Angiotensin receptor blockers (ARBs) are 
recommended only as an alternative in pa-
tients intolerant to ACE inhibitors because 
of severe cough or angioedema [24].
Beta-blockers (BBs) have a protective ef-
fect on the heart, exerted through the inhibi-
tion of adrenergic system with inotropic and 
negative chronotropic effects. The use of BBs 
results in a reduction in mortality, morbidity, 
and hospitalization for HF exacerbation and 
improves the severity of symptoms [25]. The 
treatment with BBs should be initiated in 
stable patients and gradually up-titrated to 
the maximum tolerated dose, while, in case 
of exacerbation of chronic HF, it must be re-
duced or discontinued or not started (like in 
this case) [26]. Furthermore, the administra-
tion of BBs, especially cardioselective ones, in 
patients with COPD is safe and the presence 
of a COPD is no longer a contraindication 
to the use of BBs in a patient with HF [27].
Recently, a new therapeutic class of drugs 
called angiotensin receptor neprilysin in-
hibitors (ARNI) has been developed. They 
act on the renin-angiotensin-aldosterone 
system (RAAS) and the neutral endopep-
tidase system. Sacubitril/valsartan, the first 
medication of this new class, is recommend-
ed as a replacement for an ACE inhibitors 
to further reduce the risk of death and HF 
hospitalization in patients with HFrEF 
who remain symptomatic despite optimal 
treatment with BBs, ACE inhibitors, and 
mineralocorticoid receptor antagonists [28].
All the foregoing considerations are valid 
only for patients with HFrEF. Conversely, 
no therapy significantly improves survival 
or prevents hospitalizations in patients af-
fected by heart failure with normal ejection 
fraction. The objective in these patients is to 
relieve symptoms with diuretics and treat 
hypertension and other comorbidities [29].
Outcomes
The ECG revealed a sinus rhythm and a 
left bundle branch block (LBBB) in ad-
dition to the findings reported in Table I.
A severe cardiomegaly was apparent at 
the chest radiography, which revealed 
also bibasilar pulmonary edema with 
bilateral small pleural effusions.
Blood tests highlighted 4 parameters out-
side the normal range (Table II).
Transthoracic echocardiogram (TTE) 
was not yet run.
parameter detected value
Heart rate 62 bpm
PQ 0.20 s
QRS axis -30°
QRS 0.18 s
table I. 
Electrocardiography 
findings
parameter detected value normal range
Hemoglobin (g/dl) 8.1 11.5-15.5
Mean Corpuscular Volume (fl) 78 80-97
Creatinine (mg/dl) 2.4 0.6-1.5
Brain Natriuretic Peptide (pg/ml) 280 < 35
table II. Blood test 
results
picture since it is an independent factor of 
in-hospital mortality risk in patients with 
HF despite renal dysfunction [33].
5. How should this condition 
be followed up? 
(the follow up)
After hospital discharge, it was time to or-
ganize a multidisciplinary team management, 
through periodic medical examinations by the 
GP and the cardiology outpatient clinic, to fol-
low-up and monitor patient’s condition.
One of the key problems of healthcare 
system with heart failure patients is the very 
high rate of re-hospitalization. Up to 25% 
of patients hospitalized with HF are read-
mitted within 30 days [34] and a re-hospi-
talization is one of the strongest prognostic 
predictors for augmented mortality too [35].
The goal of HF management is to orga-
nize a seam-less system of care that em-
braces both the hospital and the community 
throughout the healthcare process. A close 
integration between GPs, hospital and ter-
ritory cardiologists, specialist nurses, social 
workers, etc. can reduce HF hospitalization 
and mortality in patients discharged from 
the hospital [36] and decrease medical costs 
[37]. Multidisciplinary team management 
is also essential for the full implementation 
of non-pharmacological therapy through 
weight monitoring, avoiding salty foods, 
and harmful drugs (such as NSAIDs in this 
case), fluid intake, and possible flexible use 
of diuretic therapy [38]. An important task 
of the GP in the HF post discharge is to 
avoid medication non-adherence, which is 
a common precipitant of re-hospitalization 
and is associated with poor outcomes [39].
ConClusIon
Heart failure is a very difficult disease to 
frame and diagnose, and unfortunately signs 
and symptoms are highly nonspecific. Gen-
eral practitioners may have unique insight 
100 Clinical  Management  Issues   2017; 11(2) © 2017 The Authors. Published by SEEd srl. This is an open access article under 
the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0)
From laboratory to bedside: A case report of a concise and pragmatic approach on heart failure
package of tests both in the acute phase and 
during the follow-up. The organization of a 
multidisciplinary intervention, focused on 
both the patient and the caregiver, is of no 
less importance and it results in the reduc-
tion in hospital admission rate and mortality.
Key points
 y Clinical history and physical examination may indicate the presence of heart failure
 y Laboratory tests (e.g., natriuretic peptides) and instrumental exams allow physicians to 
diagnose and manage patients with heart failure in everyday medical practice
 y NSAID intake may act as precipitating factor for HF
 y The organization of a multidisciplinary intervention may be a very useful resource, result-
ing in the reduction in the rate of hospital admissions and mortality for HF
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